A groundbreaking phase III trial presented at ASCO has identified a novel first-line option for patients with recurrent or metastatic head and neck squamous cell carcinoma. The ultra-low-dose immunotherapy combination, TMC-I, significantly improved overall survival compared with the standard paclitaxel and carboplatin regimen.
The open-label trial randomized 422 patients to either TMC-I-a combination of weekly methotrexate, daily celecoxib and erlotinib, and just 20 mg of nivolumab every three weeks-or standard chemotherapy. The study population was challenging: median age 49.5 years, 85.5% male, and nearly 79% used oral tobacco.
Patients on TMC-I lived a median of 10.3 months compared with 6.2 months on chemotherapy-a 44% reduction in the risk of death. One-year survival was 46% versus 23%, and six-month survival 69% versus 52%. Progression-free survival more than doubled, and objective response rates were 53.4% versus 24.1%.
Safety also favored TMC-I, with fewer grade 3 or higher adverse events (34.1% vs. 46.4%) and no treatment-related deaths. Quality of life was preserved. At approximately $230 per month, the regimen offers a cost-conscious alternative, particularly where standard pembrolizumab or cetuximab is difficult to access.